Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26643162 | 0.91 | LMNA (0.48) | PIK3CDLMNAALOX15 | |
| SCHEMBL11951494 | 0.88 | — | — | |
| SCHEMBL20725781 | 0.88 | PIK3CD (0.41) | PIK3CDLMNA | |
| SCHEMBL9576634 | 0.87 | — | — | |
| SCHEMBL7877055 | 0.87 | — | — | |
| SCHEMBL7876260 | 0.87 | — | — | |
| SCHEMBL14310977 | 0.86 | — | — | |
| SCHEMBL1801481 | 0.86 | — | — | |
| SCHEMBL17151375 | 0.86 | PIK3CD (0.30) | PIK3CD | |
| SCHEMBL5159410 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228459-A1 | ESTERS AND ETHERS OF 3-METHYL-PENTANE-DIOL AND UNSATURATED DERIVATIVES THEREOF AND THEIR USE AS AROMA CHEMICAL | BASF SE (DE) | 2021-07-29 | — | — | US | claimed |
| EP-3784762-A1 | ESTERS AND ETHERS OF 3-METHYL-PENTANE-DIOL AND UNSATURATED DERIVATIVES THEREOF AND THEIR USE AS AROMA CHEMICAL | BASF SE (DE) | 2021-03-03 | — | — | EP | claimed |
| EP-3784762-B1 | ESTERS AND ETHERS OF 3-METHYL-PENTANE-DIOL AND UNSATURATED DERIVATIVES THEREOF AND THEIR USE AS AROMA CHEMICAL | BASF SE (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| US-20210228459-A1 | ESTERS AND ETHERS OF 3-METHYL-PENTANE-DIOL AND UNSATURATED DERIVATIVES THEREOF AND THEIR USE AS AROMA CHEMICAL | BASF SE (DE) | 2021-07-29 | — | — | US | disclosed |
| EP-3784762-A1 | ESTERS AND ETHERS OF 3-METHYL-PENTANE-DIOL AND UNSATURATED DERIVATIVES THEREOF AND THEIR USE AS AROMA CHEMICAL | BASF SE (DE) | 2021-03-03 | — | — | EP | disclosed |
| CN-112020549-A | Esters and ethers of 3-methylpentanediol and unsaturated derivatives thereof and use thereof as aromachemicals | 巴斯夫欧洲公司 | 2020-12-01 | — | — | CN | disclosed |
| EP-3561029-A1 | ESTERS AND ETHERS OF 3-METHYL-PENTAN-DIOL AND UNSATURATED DERIVATES THEREOF AND THEIR USE AS AROMA CHEMICAL | BASF SE (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-20170247395-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-31 | — | — | US | disclosed |
| US-9688695-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9605024-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| US-9274419-B2 | Blue photosensitive resin composition for color filter and application thereof | CHI MEI CORPORATION (TW) | 2016-03-01 | — | — | US | disclosed |
| US-20150268554-A1 | BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND APPLICATION THEREOF | CHI MEI CORPORATION (TW) | 2015-09-24 | — | — | US | disclosed |
| US-20130222738-A1 | COLOR LIQUID CRYSTAL DISPLAY DEVICE | CHI MEI CORPORATION (TW) | 2013-08-29 | — | — | US | disclosed |
| US-8207329-B2 | Synthesis of chlorins and phorbines with enhanced red spectral features | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-7875594-B2 | Using oligonucleotide immunostimulant mixture with drug; Modification of an immunostimulatory oligonucleotide to optimally present 5' ends dramatically enhances its anti-cancer activity | IDERA PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | US | disclosed |
| US-20090227553-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-10 | — | — | US | disclosed |
| US-20080206265-A1 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | IDERA PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-4288454-A | Antiviral 1-adamantyl-3-(phenylsulfonyl)thioureas | HOFFMAN-LA ROCHE INC. (US) | 1981-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227553-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | CRY1, CRY2, HCCS | PIK3CD 1222/4885LMNA 4246/4885ALOX15 3803/4885 |
| US-20210228459-A1 | ESTERS AND ETHERS OF 3-METHYL-PENTANE-DIOL AND UNSATURATED DERIVATIVES THEREOF AND THEIR USE AS AROMA CHEMICAL | FFAR3, ELOVL3, ACMSD | PIK3CD 1060/4885LMNA 908/4885ALOX15 74/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | PIK3CD 2401/4885LMNA 2818/4885ALOX15 2174/4885 |
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | PRLHR, GHRHR, TRHR | PIK3CD 3484/4885LMNA 3213/4885ALOX15 3779/4885 |
| US-20170247395-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | PIK3CD 2326/4885LMNA 2928/4885ALOX15 2114/4885 |
| US-20080206265-A1 | SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS | CD74, CD47, DCLRE1B | PIK3CD 1736/4885LMNA 4770/4885ALOX15 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.